|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
NF-��B |
|
Ƥ���� |
|
��֢ |
| ��������������� | |
|
������ |
|
�ĺ�Ȫ |
|
�� |
| PubMed | |
|
Article by |
|
Article by |
|
Article by |
������-��B����֢��Ƥ����
������, �ĺ�Ȫ, Ф��
���ϴ�ѧ���Ŷ�ҽԺƤ���� ��ɳ 410011
������-��B/Rel������һ�־��ж���ת¼�������õĵ�����,������ֻ����ת¼;����֢��Ӧ������Ӧ���Լ�����ϸ���Ļ��ת���͵�����һЩ��Ҫ�IJ������������ء���Ҫ���ۺ�����-��B��ijЩ��֢��Ƥ����,����Ӧ��Ƥ�ס���м���������֯�����չ���Ƥ�����������������õ��о���չ��
[2] Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest, 2001, 107:241-246.
[3] Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 1999, 18:6853-6866.
[4] Anest V, Hanson JL, Cogswell PC, et al. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature, 2003, 423:659-663.
[5] Bell S, Degitz K, Quirling M,et al. Involvement of NF-kappaB signalling in skin physiology and disease. Cell Signal, 2003, 15:1-7.
[6] Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med, 1999, 341:1817-1828.
[7] Kaburagi Y, Shimada Y, Nagaoka T, et al. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1alpha, MIP-1beta, and eotaxin) in patients with atopic dermatitis. Arch Dermatol Res, 2001, 293:350-355.
[8] Huber MA, Denk A, Peter RU,et al. The IKK-2/Ikappa Balpha /NF-kappa B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in Ikappa Balpha -deficient mice. J Biol Chem, 2002, 277:1268-1275.
[9] Kraft S, Novak N, Katoh N, et al. Aggregation of the high-affinity IgE receptor Fc(epsilon)RI on human monocytes and dendritic cells induces NF-kappaB activation. J Invest Dermatol, 2002, 118:830-837.
[10] Kraft S, Bieber T. Fc epsilon ri-mediated activation of transcription factors in antigen-presenting cells. Int Arch Allergy Immunol, 2001, 125:9-15.
[11] Danning CL, Illei GG, Hitchon C, et al. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum, 2000, 43:1244-1256.
[12] Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today, 1999, 20:40-46.
[13] Wissink S, van Heerde EC, vand der Burg B, et al. A dual mechanism mediates repression of NF-kappaB activity by glucocorticoids. Mol Endocrinol, 1998, 12:355-363.
[14] Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol, 2002, 2:725-734.
[15] Khaled AR, Soares LS, Butfiloski EJ, et al. Inhibition of the p50 (NKkappaB1) subunit of NF-kappaB by phosphorothioate-modified antisense oligodeoxynucleotides reduces NF-kappaB expression and immunoglobulin synthesis in murine B cells. Clin Immunol Immunopathol, 1997, 83:254-263.
[16] Becker H, Stengl G, Stein M, et al. Analysis of proteins that interact with the IL-2 regulatory region in patients with rheumatic diseases. Clin Exp Immunol, 1995, 99:325-330.
[17] Monici MC, Aguennouz M, Mazzeo A, et al. Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology, 2003, 60:993-997.
[18] Burgos P, Metz C, Bull P, et al. Increased expression of c-rel, from the NF-kappaB/Rel family, in T cells from patients with systemic lupus erythematosus. J Rheumatol, 2000, 27:116-127.
[19] Wong HK, Kammer GM, Dennis G, et al. Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J Immunol, 1999, 163:1682-1689.
[20] Abeyama K, Eng W, Jester JV, et al. A role for NF-kappaB-dependent gene transactivation in sunburn. J Clin Invest, 2000, 105:1751-1759.
[21] Djavaheri-Mergny M, Gras MP, Mergny JL, et al. UV-A-induced decrease in nuclear factor-kappaB activity in human keratinocytes. Biochem J, 1999, 338:607-613.